Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease
The relationship between baseline amyloid beta load and treatment benefit in a large population after exposure to an amyloid beta-directed antibody provides insight into which subpopulations are likely to benefit from this class of treatment.
Authors
- Holly M. Brothers (ORCID: https://orcid.org/0000-0001-8116-2682)
- Jackson Burton (ORCID: https://orcid.org/0000-0002-0910-2041)
- Gioacchino Curiale (ORCID: https://orcid.org/0000-0001-8236-7698)
- Tao Sun (ORCID: https://orcid.org/0000-0001-7255-9039)
- R. Matthew Hutchison (ORCID: https://orcid.org/0000-0002-3670-4945)
- Jennifer Murphy (ORCID: https://orcid.org/0000-0003-2751-184X)
- Gersham Dent
- Ken Kowalski
Institutions
- Biogen (United States) (US)
- Photometrics (United States) (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1016/j.tjpad.2025.100202
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Biogen